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Background: Intima-media thickness (IMT) of the common carotid artery is a surrogate end point of cardiovascular
disease (CVD). Identifying the factors associated with a higher IMT may contribute to the identification of subjects
with higher CVD risk. Our objective was to compare the common carotid IMT of type 1 diabetes patients to healthy
control subjects. The secondary objective was to determine factors associated with a higher carotid IMT.
Methods: We conducted a cross-sectional study between March 2009 and October 2013, comprising 127 type 1
diabetes patients and 125 control subjects matched by age, gender and body mass index (BMI). Carotid IMT was
measured using semi-automated edge detection software.
Results: Type 1 diabetes patients had a higher median IMT compared with control subjects (0.538; IQR: 0.500-0.607
vs 0.513 mm; IQR: 0.481-0.557, respectively p = 0.001). Women with type 1 diabetes had a higher median IMT
difference compared to the control group (0.537; IQR: 0.495-0.596 vs 0.502 mm; IQR: 0.472-0.543, respectively
p = 0.003) than did men with type 1 diabetes (0.547; IQR: 0.504-0.613 vs 0.528 mm; IQR: 0.492-0.575, respectively
p = 0.2). Age and diabetes duration had an additive effect on the IMT of type 1 diabetes patients. Multivariate
gamma regression model analysis showed that in type 1 diabetes patients, the IMT was associated with age (Exp
(β) = 1.006, p < 0.001), duration of diabetes (Exp (β) = 1.004, p = 0.001), BMI (Exp (β) = 1.005, p = 0.021), family history
of type 2 diabetes (Exp (β) = 1.044, p = 0.033), total cholesterol (Exp (β) = 0.999, p = 0.001) and creatinine clearance
(Exp (β) = 1.000, p = 0.043).
Conclusions: Patients with type 1 diabetes have increased IMT, a marker of subclinical atherosclerosis. The CVD risk
may be similar between men and women with type 1 diabetes, suggesting a loss of gender protection. Also, CVD
risk may be higher in those with a family history of type 2 diabetes. Prospective studies are needed to confirm the
predictive value of these findings and the causal effect between IMT and CVD in patients with type 1 diabetes.
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There is a worldwide increase in type 1 diabetes incidence
[1,2]. The disease can evolve to chronic complications,
resulting in higher morbidity and mortality and conse-
quently higher costs [1-3]. Furthermore, there has been
an increase in the prevalence of overweight and obese
patients in the type 1 diabetes population all over the
world, including Brazil [4,5].
The cardiovascular disease (CVD) risk in type 1 diabetes
is approximately 10 times higher than that in the general
population, even in the absence of classical risk factors
and adequate metabolic control [6-15]. Type 1 diabetes
patients are continuously exposed to a hyperglycemic en-
vironment and other CVD risk factors, such as insulin
dosage and the presence of chronic complications [16]. All
of these risk factors are present at a very young age, result-
ing in progressive endothelial dysfunction that results in
the atherosclerosis process [12,14,15]. One study showed
that the soluble form of the membrane glycoprotein
CD146 (sCD146) derived from endothelium cells is in-
creased in individuals with cardiovascular and inflamma-
tory disease and is associated with endothelial dysfunction
[17]. Even in type 1 diabetes patients without chronic
complications there is a mild chronic inflammatory state,
which can be observed as an elevation of acute phase
proteins (such as C-reactive protein (CRP)) that may
also contribute to atherosclerosis [18]. Furthermore, some
other unknown CVD risk factors might be present as
there is still a residual CVD risk even in patients with
excellent metabolic control [16].
More accurate methods for detection of sub-clinical
atherosclerosis would be useful for identifying pa-
tients with type 1 diabetes with high CVD risk. The
complex involving the intima and media layer thick-
ness (IMT) of the common carotid artery measured
by ultrasound is related to subclinical atherosclerosis
process and higher CVD risk in type 1 diabetes pa-
tients [7,19-21]. Furthermore, it has been suggested
that there is a linear correlation between the increase
in total and cardiovascular death and the increase in
IMT [22-25]. This measurement is a simple and non-
invasive procedure [22,26,27].
Intensive glucose control is able to postpone the IMT
increase, although it does not prevent it [6,12]. The
DCCT/EDIC study showed that though both the original
intensive and conventional treatment groups had the
same glycated hemoglobin (HbA1c) during the 12 years
of the EDIC study, the original intensive treatment group
still had a thinner IMT [28]. Many factors may influence
the IMT and, in fact, there may be some unrecognized
factors associated with it [12,13,24,29-33].
The primary objective of this study was to compare the
carotid IMT between type 1 diabetes patients and healthy
control. The secondary objective was to determine theclinical and laboratorial variables that are associated with
a thicker carotid IMT in these populations.Methods
This was a cross-sectional, single center study conducted
between March 2009 and October 2013 in consecutive
patients with type 1 diabetes who regularly attended a
tertiary care diabetes outpatient unit at Pedro Ernesto
University Hospital. These patients were matched to
healthy control subjects by age, gender and body mass
index (BMI). Age was matched by age group with a
range of five years because of our difficulty in finding older
healthy control subjects. Control subjects were recruited
among the patients’ spouses and relatives, university
students and hospital employees. The study was ap-
proved by the local research ethics committee of Pedro
Ernesto University Hospital, Rio de Janeiro State Univerity,
Rio de Janeiro, Brazil. Participants were subjected to
clinical and laboratory evaluation.
Initially, written informed consent was obtained from
all participants. Subjects were submitted to an interview
for demographic and clinical information and underwent
physical examination. On the morning of the interview,
subjects brought in the first 10- hour overnight urine
sample, and fasting and post-prandial blood samples
were collected. Subjects were then conducted to the
Echo laboratory acclimatized room to perform the IMT
measurement.
The inclusion criteria included individuals older than
10 years, patients with type 1 diabetes for more than five
years, patients who continuously used insulin since diag-
nosis and healthy control subjects. The exclusion criteria
included type 1 diabetes patients and healthy control
subjects who were unable to tolerate dorsal decumbency
for long periods, a previous history of invasive procedure
in the carotid artery, chronic usage of glucocorticoids,
asthma or chronic obstructive pulmonary disease, kidney
disease, liver failure, thyroid disease and control subjects
with previous histories of high cholesterol levels or using
cholesterol-lowering drugs, hypertension or using pressure-
lowering drugs and cardiovascular disease.
We followed the American Diabetes Association (ADA)
statement for the definition of childhood and adolescence.
[34]. BMI was calculated by dividing the weight in kilo-
grams by the squared height in meters. Overweigh was
defined as a BMI ≥ 25 for adults or ≥ 85th percentile for
children, and obesity was defined as a BMI ≥ 30 for adults
or ≥ 95th percentile for children and adolescents [35].
Blood pressure (BP) was calculated using the mean of
the three measurements. Adult subjects were classified
as having hypertension when the mean was higher than
140 mmHg for systolic blood pressure (SBP) and/or
90 mmHg for diastolic blood pressure (DBP) [36,37].
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hypertension if SBP or DBP was ≥ 95th percentile for
age, sex and height [35].
Glucose control was assessed by fasting glucose (FG)
and HbA1c (high performance liquid chromatography
(HPLC), Bio-Rad Kit, hemoglobin testing system equip-
ment from Bio-Rad Lab., Irvine, USA. Reference values =
4.0 to 6.0%).
Uric acid, serum creatinine, triglycerides, High density
cholesterol (HDL) and total cholesterol levels were
measured by enzymatic techniques (Cobas Mira; Roche,
Bohemia, NY, USA). Low density cholesterol (LDL) was
calculated using the Friedewald equation, except when
the triglyceride levels were higher than 400 mg/dL [38].
Creatinine clearance was calculated using the Cockcroft-
Gault equation. Urinary albumin excretion rate (UAER)
was estimated by solid-phase competitive chemilumin-
escent enzyme immunoassay (sensitivity of 0.5 mcg ⁄mL;
Immulite 1000 Systems; DPC Medlab, Los Angeles,
CA, USA) with intra- and inter-assay variation coeffi-
cients of 4.4 and 6.1%, respectively. Serum CRP was
measured using a highly sensitive immunonephelome-
try assay (Behring Nephelometer; Behring, Marburg,
Germany) with a detection limit of 0.01 mg/dl and
intra- and inter-assay variation coefficients of 1 and
5.3%, respectively.
The IMT image was digitally recorded using a commer-
cially available system (Envisor CHD, Philips, Bothell,
WA, USA) equipped with a linear L12-13Hz transducer.
The IMT was measured using the semi-automated edge-
detection software package Q-LAB Advanced Ultrasound
Quantification Software version 7.1, Philips. This soft-
ware measured the IMT in millimeters with a three
decimal places precision. Measurements were obtained
according the American Society of Echocardiography
recommendations [26].
A single examiner performed all IMT images in a quiet,
dark, acclimatized room, after the patient rested for at
least five minutes. A bilateral transversal scanning from
the common carotid artery and its visible ramifications
was performed to look for apparent plaques. The distal
one centimeter length of the common carotid IMT image
was stored in a digital media after positioning the trans-
ducer longitudinal to the carotid vessel. The images were
taken in three different angles, posterior, lateral and anter-
ior, for each right and left common carotid artery. The
IMT was measured off-line using the semi-automated
edge-detection software by two independent skilled exam-
iners who were blinded for the condition of the subject
analyzed.
Statistical analysis was performed using the SPSS
software version 21 (IBM Corp., USA). To detect a
0.021 mm difference in the IMT between type 1 dia-
betes and control subjects with a statistical power of80%, we would need 120 individuals in each group. To
determine the agreement between both examiners, we
calculated the intra-class coefficient (95% CI) and per-
formed the Bland-Altman box-plot. Data are presented
in median and interquartile range (IQR). The non-
parametric data were analyzed using the Mann–Whitney
U test or the unpaired t test when applicable. The bivari-
ate analysis was performed using gamma regression
model between the IMT and the variables analyzed.
Those variables with a p value < 0.1 in the bivariate
model were included in the multivariate gamma regres-
sion model, which was performed in backwards. To
avoid multicollinearity, when two or more variables
were a measure of the same risk factor, we chose the
most significant one. We performed the multivariate
gamma model analysis in backwards because there were
a lot of variables to be analyzed.Results
Overview of demographic and laboratorial data of the
studied population
Characteristics of the study population are shown in
Table 1. In patients with type 1 diabetes, age ranged from
14 to 63 years old and in the control group, age ranged
from 14 to 57 years old. There was only one patient with
type 1 diabetes who was older than 57 years. Compared to
the control group, patients with type 1 diabetes had lower
alcohol consumption (9.6 vs 10.4%, p < 0.001), higher me-
dian FG (117 mg/dL; IQR: 78–260 vs 78 mg/dL; IQR:
70.5-85.5, p < 0.001), higher median HbA1c (8.9%; IQR:
7.8-10.5 vs 5.4%; IQR: 5.2-5.8, p < 0.001), lower median
creatinine (0.86 mg/dL; IQR: 0.7-1.0 vs 0.93 mg/dL; IQR:
0.77-1.09, p = 0.007), lower median triglycerides (74.5 mg/
dL; IQR: 57–108.8 vs 91 mg/dL; IQR: 68–129.5, p = 0.05),
lower median uric acid (3.7 mg/dL; IQR: 2.9-4.5 vs
5.1 mg/dL; IQR: 4.0-6.3, p < 0.001) and higher median
UAER (8.56 mcg/min; IQR: 4.31-25.33 vs 3.39 mcg/min;
IQR: 2.11-5.99, p < 0.001).
Among patients with type 1 diabetes, 74.8% had dia-
betes duration ≥ 10 years, and 32.3% had a diabetes dur-
ation ≥ 20 years. There were 45.9% with HbA1c > 9%
and 11.9% with HbA1c ≤ 7%. Additionally, in patients
with the type 1 diabetes, there were 15% of subjects
with a BP ≥ 140×90 mmHg or over the 95% percentile
for children and adolescents, 9.6% with a current history
of smoking, 33.1% with BMI of ≥ 25 kg/m2 or over the
85% percentile for children and adolescents, 7.9% with a
HDL < 40 mg/dL for men or < 50 mg/dL for women,
27.9% with a LDL > 100 mg/dL, 33.9% with a CRP >0.3
and 21.3% with an UAER > 30 mcg/min.
Among the control group, 10.4% subjects had current
history of smoking, 47% with a BMI of ≥ 25 or over the
85% percentile for children and adolescents, 12% with a
Table 1 Clinical and laboratory data in patients with type 1 diabetes and control subjects
Type 1 diabetes Control P
Demographic data
N (% male) 127 (45.7) 125 (40.8) 0.4
Age (years) 32 (23–42) 29 (22–39.5) 0.08
Age at diagnosis (years) 15 (10–22)
Duration of diabetes (years) 14 (10–21.8)
Past history of hypertension (%) 24.8%
Current smoke (%) 9.6 10.4 0.8
Current alcohol consumption (%) 30.4 58.3 <0.001
Current exercise practice (%) 42,4 50.6 0.3
Family history
Family history of type 2 diabetes (%) 29,8 25.2 0.5
Family history of type 1 diabetes (%) 19.2 18.3 0.9
Family history of hypertension (%) 64 52.2 0.07
Family history of CVD (%) 21 13 0.1
Anthropometric data and insulin dose
BMI (kg/m2) 23.6 (21.6-26.2) 24.3 (21.6-28) 0.2
SBP (mmHg) 120 (110–125.8) 113 (105–120) 0.06
DBP (mmHg) 70 (70–80) 70 (68.5-80) 0.2
Waist (cm) 81 (74–88) 81 (73.1-89.9) 0.9
WHR 0.86 (0.8-0.9) 0.85 (0.79-0.91) 0.5
Insulin/weight (U/Kg) 0.81 (0.59-1.07)
Laboratory data
Fasting glucose (mg/dL) 117 (78–260) 78 (70.5-85.5) <0.001
HbA1c (%) 8.9 (7.8-10.5) 5.4 (5.2-5.8) <0.001
Creatinine (mg/dL) 0.86 (0.7-1.0) 0.93 (0.77-1.09) 0.007
Creatinine clearance (mL/min) 112.7 (88.5-131.3) 103.5 (87.4-119.4) 0.1
Uric acid (mg/dL) 3.7 (2.9-4.5) 5.1 (4.0-6.3) <0.001
Total cholesterol (mg/dL) 163 (148–189) 167.5 (146–197.8) 0.3
Triglycerides (mg/dL) 74.5 (57–108.8) 91 (68–129.5) 0.05
HDL (mg/dL) 55.7 (44.7-67.4) 54.9 (44.1-65.8) 0.3
LDL (mg/dL) 90.1 (74.9-105.3) 96 (73.3-115.5) 0.07
CRP (mg/dL) 0.144 (0.066-0.340) 0.120 (0.030-0.320) 0.2
UAER (mcg/min) 8.56 (4.31-25.33) 3.39 (2.11-5.99) <0.001
IMT data
IMT on the right (mm) 0.533 (0.497-0.600) 0.513 (0.478-0.555) 0.002
IMT on the left (mm) 0.530 (0.490-0.610) 0.510 (0.475-0.562) 0.005
Total IMT (mm) 0.538 (0.500-0.607) 0.513 (0.481-0.557) 0.001
N = Number, CVD = Cardiovascular disease, BMI = Body mass index, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, WHR =Waist to hip ratio,
U = International units, HbA1c = Glycated hemoglobin, HDL = High density lipoprotein, LDL = Low density lipoprotein, CRP = C reactive protein, UAER = Urinary
Albumin excretion rate, IMT = intima media thickness. Data are presented in median and interquartile range (IQR).
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with a LDL > 100 mg/dL and 33.3% with CRP > 0.3. There
were no control subjects with an UAER ≥30 mcg/min or
BP ≥ 140×90 mmHg or over the 95% percentile for
children and adolescents.Overview of IMT agreement between the two examiners
and difference between right and left IMT
There was a high agreement between both independent
analyzers using the intra-class coefficient (0.963 95%
CI = 0.950-0.973, p < 0.001) (Figure 1).
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Figure 1 Bland-Altman agreement boxplot between examiners. Lines: a =mean difference of IMT, b = +1.96SD mean difference of IMT,
c = −1.96SD mean difference of IMT. IMT = intima media thickness.
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mean IMT in any group, as shown in Table 2. Therefore
the total mean IMT was employed for statistical analysis.
Overview of IMT data of the whole population
Type 1 diabetes patients had higher median right, left and
total carotid IMT compared with the control subjects
(0.533 mm; IQR: 0.497-0.600 vs 0.513 mm; IQR: 0.478-
0.555, p = 0.002, 0.530 mm; IQR: 0.490-0.610 vs 0.510 mm;
IQR: 0.475-0.562, p < 0.005 and 0.538 mm; IQR: 0.500-
0.607 vs 0.513 mm; IQR: 0.481-0.557, p = 0.001, respect-
ively). The data are shown in Table 1.
The difference in median IMT between patients with
type 1 diabetes and the control group was higher in
women (0.537 mm; IQR: 0.495-0.596 vs 0.502 mm;
IQR: 0.472-0.543, respectively p = 0.003) than in men
(0.547 mm; IQR: 0.504-0.613 vs 0.528 mm; IQR: 0.492-
0.575, respectively p = 0.2). The influence of age on ca-
rotid IMT in type 1 diabetes patients and control subjects
is shown in Figure 2. The variables associated with IMT
in the bivariate gamma regression model are listed in
Table 3.
Multivariate gamma regression analysis in patients with
type 1 diabetes showed that having a family history of type
2 diabetes increased the IMT by 4.4%. For each year of
age, there was a 0.6% increase in IMT, for each year ofTable 2 Comparison between right and left IMT measuremen
Right IMT (mm) Le
Type 1 diabetes 0.533 (0.497-0.600) 0,53
Control 0.513 (0.478-0.555) 0.51
IMT = Intima-Media Thickness. Data are presented in median and interquartile rangediabetes duration, there was a 0.4% increase in IMT and
for each one point increase in BMI there was a 0.5% in-
crease in IMT. For each increase of 1 mg/dL in total
cholesterol, there was a 0.1% reduction in IMT, and for
each 1 mg/min increase in creatinine clearance, there
was an almost 0.0%, but statistically significant increase
in IMT, as shown in Table 4 and Figure 2.
Multivariate gamma regression model analysis in the
control group IMT showed that the male gender was asso-
ciated with a 5.4% increase in IMT, having a family history
of type 2 diabetes was associated with a 4.9% increase in
IMT. For each year of age, there was a 0.4% increase in
IMT and for each 1 point increase in BMI, there was a
0.4% increase in IMT. Data are shown in Table 4 and
Figures 2 and 3.
Comparing patients with type 1 diabetes with or without
family history of type 2 diabetes there was no difference in
median BMI (24.1 kg/m2; IQR: 22.5-27.45 vs 23.5 kg/m2;
IQR: 21–25.3, respectively, p = 0.08) or in median LDL
(93.5 mg/dL; IQR: 80.8-113.4 vs 84.6 mg/dL; IQR: 71.9-98,
respectively, p = 0.07). Comparing control subjects with or
without family history of type 2 diabetes there was no dif-
ference in BMI (25.6 kg/m2; IQR: 22.7-28.1 vs 24.3 kg/m2;
IQR: 21.5-28.2, respectively, p = 0.5) or in median LDL
(100.9 mg/dL; IQR: 88.3-129.8 vs 94 mg/dL; IQR: 69.7-
108.8, respectively, p = 0.1).ts in patients with type 1 diabetes and control subjects
ft IMT (mm) Difference (mm) p
0 (0.490-0.610) 0.003 0.7























Figure 2 Association of IMT with age in control subjects and patients with type 1 diabetes. IMT = intima media thickness.
Andrade et al. Cardiovascular Diabetology 2014, 13:87 Page 6 of 11
http://www.cardiab.com/content/13/1/87Discussion
Our study showed that in our sample, patients with type
1 diabetes had a higher IMT compared with the control
subjects. Despite having type 1 diabetes for a relatively
long time, our patients with type 1 diabetes had a lower
IMT than expected, similar to the findings of another
study [13]. In our study, in patients with type 1 diabetes,
having a family history of type 2 diabetes was associated
with a 4.4% increase in carotid IMT and unlike the control
group, women with type 1 diabetes had a IMT as high
as men.
In the control group, the female gender was associated
with a thinner IMT, but this association was not found
in our patients with type 1 diabetes. A study that evalu-
ated the distribution of IMT according to age in the gen-
eral population showed that men had a higher IMT
compared with women [39]. These findings could reflect
a loss of gender protection for CVD risk in women with
type 1 diabetes as suggested by The Diabetes UK Cohort
Study and another study [40,41]. In fact, in patients with
type 1 diabetes, women may have a higher increase in
CVD risk compared with men [8]. In a cohort of 23,000
patients with type 1 diabetes the CVD risk in women
with diabetes was not only greater than that for women
without diabetes but was also considerably higher than
that for men without diabetes [40]. Another study dem-
onstrated that women had a higher arterial stiffness
measured at the carotid and radial arteries compared to
men [42]. The EURODIAB PCS found that in patientswith type 1 diabetes, the CVD risk may be increased
approximately 9–29 times in women and 4–9 times in
men compared to individuals without diabetes [43].
The higher IMT found in our patients with type 1
diabetes was not associated with current parameters of
glycemic control. This findings are similar to the find-
ings in the DCCT/EDIC study, in which carotid IMT
was only associated with the HbA1c six years before the
IMT measurement [28]. This delayed effect suggests a
glycemic memory that favors an early and intensive
metabolic control [44].
Among all of the factors associated with IMT, age may
be a major one and in our study it was associated with a
higher IMT in both groups, which is in accordance with
another study [45]. In fact, age is the most important
characteristic in IMT normality tables [26]. Furthermore,
our findings suggest that there was a higher impact of
age in the IMT of patients with type 1 diabetes than in
the IMT of the control subjects. This higher impact may
be partly due to the duration of the disease. It is import-
ant to note that in one study, it was found that CVD
was the main cause of death in patients with type 1 dia-
betes, primarily in those who had had diabetes for more
than 20 years [46].
A family history of type 2 diabetes was an important
factor that influenced the IMT in both groups. The
DCCT/EDIC study found that patients with type 1 dia-
betes and family histoy of type 2 diabetes in the intensive
treatment group had a greater increase in the carotid
Table 3 Bivariate gamma regression model between IMT and clinical and laboratory data
Type 1 Diabetes Control
Exp (β) (95% CI) p Exp (β) (95% CI) p
Demographic data
Age 1.009 (1.007-1.011) <0.001 1.005 (1.004-1.007) <0.001
Gender (men vs women) 1.036 (0.981-1.093) 0.202 1.048 (1.010-1.087) 0.013
Duration of diabetes 1.010 (1.008-1.012) <0.001
Diagnosis of hypertension 1.133 (1.076-1.193) <0.001
Current smoke 1.040 (0.998-1.096) 0.134 1.029 (0.969-1.093) 0.347
Current alcohol consumption 0.975 (0.925-1.027) 0.335 1.001 (0.963-1.040) 0.979
Current exercise practice 0.991 (0.937-1.048) 0.757 0.993 (0.956-1.032) 0.731
Family history
Family history of type 2 diabetes 1.058 (1.002-1.118) 0.042 1.073 (1.027-1.120) 0.001
Family history of type 1 diabetes 1.038 (0.271 to 1.109) 0.273 1.010 (0.961-1.063) 0.685
Family history of hypertension 1.112 (1.054-1.173) <0.001 1.020 (0.981-1.060) 0.322
Family history of CVD 1.108 (1.036-1.185) 0.003 1.021 (0.967-1.077) 0.458
Anthropometric data
SBP 1.004 (1.002-1.006) <0.001 1.002 (1.001-1.004) 0.008
DBP 1.003 (1.001-1.005) 0.001 1.003 (1.001-1.005) 0.008
BMI 1.012 (1.005-1.018) <0.001 1.007 (1.003-1.012) 0.001
Waist 1.004 (1.002-1.007) 0.001 1.004 (1.002-1.005) <0.001
Hip 1.002 (0.999 to 1.005) 0.161 1.003 (1.001-1.005) <0.001
WHR 1.811 (1.220-2.691) 0.003 1.465 (1.121-1.915) 0.005
Laboratory data
Fasting glucoses 1.000 (1.000-1.000) 0.622 1.001 (1.000-1.002) 0.185
Glycated hemoglobin 0.987 (0.974-0.999) 0.041 1.054 (1.002-1.110) 0.043
Creatinine 1.026 (1.017-1.034) <0.001 1.045 (0.960-1.136) 0.311
Creatinine clearance (mg/min) 0.999 (0.998-1.000) 0.001 1.000 (1.000-1.001) 0.410
Total cholesterol 0.999 (0.998-1.000) 0.050 1.001 (1.000-1.001) 0.005
Triglycerides 1.000 (1.000-1.000) 0.809 1.000 (1.000-1.001) 0.006
LDL 1.000 (0.999- 1.001) 0.626 1.001 (1.000-1.001) 0.009
HDL 0.998 (0.997-1.000) 0.018 1.000(0.999-1.001) 0.682
Uric acid 0.993 (0.974-1.012) 0.460 1.008 (0.995-1.021) 0.219
CRP 0.974 (0.879-1.078) 0.607 1.024 (0.975-1.075) 0.343
UAER 1.000 (1.000-1.000) 0.135 1.000 (0.998-1.002) 0.931
Exp (β) = Exponential beta coefficient; CI = Confidence interval; CVD = Cardiovascular disease; SBP = Systolic blood pressure; DBP = Diastolic blood pressure;
BMI = Body mass index; WHR =Waist to hip ratio; LDL = Low density lipoprotein; HDL = High density lipoprotein; CRP = C reactive protein; UAER = Urinary albumin
excretion rate.
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emphasize that in the general population, a family his-
tory of type 2 diabetes was a major determinant of
endothelial dysfunction and this was able to predict
the progression of carotid IMT [48,49]. Unfortunately,
such an association was not evaluated in our study.
However, one author failed to find any association be-
tween type 1 diabetes and endothelial dysfunction [50].
In patients with Type 1 diabetes, a family history of
type 2 diabetes is associated with a metabolic profile ofinsulin resistance, increased carotid IMT and increased
CVD risk [51,52]. One study showed that in non-obese
patients with type 1 diabetes the insulin resistance was
associated with a higher IMT [53]. In our study the
association of IMT with family history of type 2 dia-
betes may reflect the insulin resistance. Another study
showed an increased prevalence of a family history of
type 2 diabetes in patients with type 1 diabetes and a
history of coronary artery disease compared with patients
with type 1 diabetes without a history of coronary artery
Table 4 Multiple gamma regression model between IMT and clinical and laboratory data
Type 1 Diabetes Control
Exp (β) (95% CI) p Exp (β) (95% CI) p
Age 1.006 (1.004-1.008) <0.001 1.004 (1.003-1.006) <0.001
Gender (Male vs Female) 1.029 (0.993-1.066) 0.1 1.054 (1.020-1.088) 0.001
Duration of diabetes 1.004 (1.002-1.007) 0.001
BMI 1.005 (1.001-1.010) 0.021 1.004 (1.000-1.008) 0.035
Family history of type 2 diabetes 1.044 (1.003-1.085) 0.033 0.049 (1.012-1.088) 0.009
Creatinine clearance 1.000 (0.999-1.000) 0.0043
Total cholesterol 0.999 (0.999-1.000) 0.001
Exp (β) = Exponential beta coefficient, 95% CI = 95% Confidence interval, BMI = Body mass index.
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family history of type 2 diabetes should be under an even
more aggressive treatment in regards to not only glucose
control but also other CVD risk factors such as blood
pressure and lipid profile.
Another important CVD risk factor is the presence of
renal dysfunction. The presence of renal dysfunction in
type 1 diabetes patients is associated with a 10- fold
increase in CVD risk compared with those patients with
type 1 diabetes without renal dysfunction [55]. In our
study, the association of IMT with creatinine clearance
in patients with type 1 diabetes may reflect the associ-
ation of CVD risk and some renal dysfunction.
The DCCT/EDIC study demonstrated that in patients
with type 1 diabetes the excess weight gain was associ-
ated with higher carotid IMT, independently of treat-
ment group [47]. In our study, the association of BMI
with IMT in both patients with type 1 diabetes and in















Figure 3 IMT and family history of type 2 diabetes in control subjects
IMT = intima media thickness.tissue on endothelial dysfunction and CVD risk as recently
demonstrated [56,57].
The positive association of IMT and total cholesterol
in patients with type 1 diabetes was an unexpected
finding.
Carotid IMT is an established surrogate end point for
CVD risk in the general population and has a strong
correlation with CVD risk factors [58]. However, there
are no longitudinal studies in type 1 diabetes showing a
causal relationship between a higher carotid IMT and
cardiovascular events, as demonstrated in the DCCT/
EDIC study [28]. In this study, after 12 years of follow
up, only 75 patients experienced cardiovascular events,
and the authors could not demonstrate a causal effect
between the increase in carotid IMT and CVD events.
Despite the high CVD mortality in patients with type 1
diabetes [40], there is no specific method for CVD
screening and no method to stratify CVD risk in these
patients. Additionally, there is difficulty in identifyingNo Yes
y of type 2 diabetes
Type 1 diabetes
Group
and patients with type 1 diabetes. CI = confidence interval,
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http://www.cardiab.com/content/13/1/87factors associated with impaired cardiac function and car-
diac remodeling as suggested by the DCCT/EDIC study
[59]. In this study, there was an association between
the mean glycated hemoglobin over the entire follow-up
period and parameters of cardiac function and structures
evaluated by cardiac magnetic resonance. However, this
study failed to find any difference between previously in-
tensive versus conventionally treated patients. In a review
of CVD in type 1 diabetes the authors state that in the
past 40 years, there was a 70% reduction in CVD mortality
in type 1 diabetes presumably because of the progress in
CVD risk management. However, CVD mortality may
increase approximately 50% for each 1% increase in
HbA1c between the ages of 45 and 64 years [44]. The
difficulty in identifying those patients with high CVD
risk was illustrated by a recent case report of a 48-
years-old woman with a long duration of type 1 diabetes
but without evidence of microvascular complication,
traditional CVD risk factors and a family history of dia-
betes. She had a rapidly progressive severe coronary
atherosclerosis and experienced a myocardial infarction
by the age of 42 [60].
The primary strength of our study resides in the fact
that all IMT data were measured using a semi-automated
edge-detection software and confirmed by a second inde-
pendent echocardiographist. Both were blinded to the
subject condition, and there was a high agreement be-
tween them. This high agreement convince us that this is
a reliable and reproducible procedure that can improve
the detection of patients with type 1 diabetes and in-
creased CVD risk. Some limitations must be addressed.
We studied the patients with type 1 diabetes in a single
center with only internal validation. Furthermore, con-
sidering that our study was a cross-sectional one, the
inference of cause-effect was not possible.Conclusion
Despite their young age, patients with type 1 diabetes have
increased IMT, which is a marker of subclinical athero-
sclerosis. The CVD risk may be similar between men and
women with type 1 diabetes, suggesting a loss of gender
protection for CVD risk in this population. The CVD risk
may even more increased in those patients with a family
history of type 2 diabetes. Future prospective studies are
needed to confirm the predictive value of these findings
and the causal effect between the carotid IMT and CVD
in patients with type 1 diabetes.
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